Correction to: Liver fibrosis assessment with multiphasic dual-energy CT: diagnostic performance of iodine uptake parameters

Yasunori Nagayama¹ • Yuki Kato¹ • Taihei Inoue¹ • Takeshi Nakaura¹ • Seitaro Oda¹ • Masafumi Kidoh¹ • Osamu Ikeda¹ • Toshinori Hirai¹

Published online: 11 May 2021
© European Society of Radiology 2021

Correction to: European Radiology

<https://doi.org/10.1007/s00330-021-07706-2>

The original version of this article, published on 25 March 2021, unfortunately contained a mistake. The

following correction has therefore been made in the original: In Table 4, the values for $\Delta\text{HU}_{\text{liver_DP}}$ (HU) in F0–2 and F0–3 groups were incorrect. The corrected table is given below. The original article has been corrected.

The online version of the original article can be found at <https://doi.org/10.1007/s00330-021-07706-2>

✉ Yasunori Nagayama
y.nagayama1980@gmail.com

¹ Department of Diagnostic Radiology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1, Honjo, Chuo-ku, Kumamoto 860-8556, Japan

Parameters	F stage		<i>p</i> value	F stage		<i>p</i> value	F stage		<i>p</i> value
	F0–1 (<i>n</i> = 47)	F2–4 (<i>n</i> = 70)		F0–2 (<i>n</i> = 66)	F3–4 (<i>n</i> = 51)		F0–3 (<i>n</i> = 88)	F4 (<i>n</i> = 29)	
Age (years)	67 ± 12	69 ± 12	0.33	68 ± 11	68 ± 13	0.78	67.9 ± 12.4	68.9 ± 9.9	0.64
Men	36 (76.6)	47 (67.1)	0.30	50 (75.8)	33 (64.7)	0.22	67 (76.1)	16 (55.2)	0.04
Body mass index (kg/m ²)	23.8 ± 3.3	24.6 ± 4.0	0.28	23.7 ± 3.2	25.0 ± 4.2	0.06	23.9 ± 3.6	25.5 ± 4.0	0.06
Hematocrit (%)	37.5 ± 6.1	37.7 ± 5.3	0.84	37.5 ± 5.7	37.8 ± 5.6	0.81	37.9 ± 6.6	37.0 ± 5.6	0.47
SSDE (mGy)									
Pre-contrast	15.6 ± 2.2	15.8 ± 3.5	0.68	15.5 ± 2.1	16.0 ± 3.8	0.38	16.1 ± 3.8	15.6 ± 2.7	0.53
PVP	17.4 ± 2.5	17.6 ± 3.2	0.70	17.3 ± 2.3	17.7 ± 3.6	0.42	18.0 ± 3.5	17.3 ± 2.7	0.36
DP	17.0 ± 2.8	17.1 ± 3.3	0.90	16.8 ± 2.6	17.4 ± 3.6	0.18	17.5 ± 3.6	16.9 ± 2.9	0.42
ΔHU parameters									
ΔHU _{liver_PVP} (HU)	62.4 ± 10.6	60.9 ± 10.2	0.44	62.3 ± 10.4	60.5 ± 10.3	0.33	61.8 ± 10.3	60.6 ± 10.6	0.59
ΔHU _{liver_DP} (HU)	36.8 ± 5.8	40.4 ± 6.4	0.001	37.2 ± 6.1	41.3 ± 6.1	< 0.001	37.9 ± 6.3	42.2 ± 5.6	0.001
ECV _{ΔHU} (%)	26.8 ± 3.7	29.6 ± 5.1	< 0.001	26.8 ± 3.7	30.7 ± 5.3	< 0.001	27.7 ± 4.5	31.0 ± 4.8	0.004
IWR _{ΔHU} (%)	40.7 ± 5.0	32.9 ± 9.7	< 0.001	40.2 ± 5.0	30.7 ± 10.1	< 0.001	38.3 ± 7.4	29.3 ± 10.2	< 0.001
ID parameters									
ID _{liver_PVP} (mg/mL)	2.43 ± 0.42	2.32 ± 0.41	0.18	2.43 ± 0.41	2.28 ± 0.40	0.06	2.39 ± 0.42	2.29 ± 0.40	0.23
ID _{liver_DP} (mg/mL)	1.42 ± 0.23	1.55 ± 0.24	0.003	1.44 ± 0.24	1.58 ± 0.23	< 0.001	1.46 ± 0.24	1.60 ± 0.23	0.008
ECV _{ID} (%)	24.0 ± 3.7	27.0 ± 4.9	< 0.001	24.1 ± 3.6	27.9 ± 5.1	< 0.001	25.0 ± 4.4	28.1 ± 4.8	0.002
IWR _{ID} (%)	41.8 ± 4.6	32.4 ± 9.1	< 0.001	40.6 ± 4.6	30.1 ± 9.4	< 0.001	38.3 ± 7.3	29.1 ± 9.5	< 0.001
Serum fibrosis markers									
APRI	0.39 ± 0.27	0.93 ± 1.01	< 0.001	0.43 ± 0.30	1.09 ± 1.13	< 0.001	0.56 ± 0.78	1.17 ± 0.85	0.001
FIB-4	2.17 ± 1.09	4.13 ± 2.42	< 0.001	2.34 ± 1.16	4.65 ± 2.56	< 0.001	2.64 ± 1.8	5.18 ± 2.33	< 0.001

Data are presented as mean ± standard deviation or number (%)

APRI alanine aminotransferase-to-platelet ratio index, DP delayed phase, FIB-4 fibrosis-4 index, ID iodine density, PVP portal-venous phase, SSDE size-specific dose estimate

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.